# ERK1/2-Integrin Signaling in Desmosome-Dyad Crosstalk

> **NIH NIH R01** · UNIVERSITY OF IOWA · 2024 · $608,195

## Abstract

PROJECT SUMMARY
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an inherited disease characterized by fibro-fatty
infiltration of the heart, life-threatening ventricular arrhythmias and sudden cardiac death, particularly in response
to sympathetic stress. ARVC is a leading cause of sudden cardiac death among young athletes with no prior
symptoms or diagnosis of cardiovascular disease. Desmosome cell-adhesion gene mutations constitute the
majority of familial ARVC cases, but it remains largely unknown how catecholamine-sensitive ventricular
tachycardia and cardiac remodeling processes are facilitated by desmosome dysfunction. Patient management
is therefore limited to improving quality of life by reducing arrhythmic symptoms or cardiac transplantation upon
advanced heart failure. To begin to uncover mechanisms inherent to ARVC, we performed unbiased mass
spectrometry analysis of ventricular samples from patients with different desmosomal gene mutations. Our
preliminary data demonstrate that integrin β1D is significantly downregulated in ARVC resulting in de-
stabilization of RyR2 ryanodine receptor Ca2+ channels that localize to cardiac dyad junctions. Mechanistically,
we find that ERK1/2 activation in response to desmosome loss results in ubiquitin-dependent degradation of
integrin β1D, RyR2 Ser-2030 phosphorylation, sarcoplasmic reticulum Ca2+ leak and arrhythmogenesis.
Importantly, hearts of our integrin β1D knockout mice exhibit ARVC-like disease with increased RyR2
phosphorylation, catecholamine-induced ventricular arrhythmias and cardiac fibrosis. We hypothesize that
communication between desmosome junctions and cardiac dyads is essential for maintaining Ca2+ homeostasis
and that ERK1/2 activation-induced loss of integrin β1D impairs this “desmosome-dyad crosstalk” thereby
promoting RyR2-dependent and catecholamine-sensitive arrhythmogenesis and fibrotic infiltration in ARVC. We
further hypothesize that interventions targeting this pathway may offer a promising approach for treating ARVC.
To test our hypothesis, we have generated three congenic knock-in mouse models using CRISPR-Cas9 that
contain mutations equivalent to those we identified from human ARVC patients. In Aim 1, we will determine the
pathogenicity of knock-in ARVC mutations in recapitulating cardiac remodeling, catecholamine-induced
arrhythmogenesis and desmosome-dyad crosstalk in mutant ARVC mice. In Aims 2 and 3, we will test whether
mutation-induced ARVC phenotypes can be effectively prevented through ERK1/2 (Aim 2) and RyR2 (Aim 3)
inhibition. We expect our studies to show that life-threatening ventricular arrhythmias and heart failure from
ARVC can be therapeutically managed by modulating desmosome-dyad crosstalk and attenuating Ca2+ handling
dysfunction.

## Key facts

- **NIH application ID:** 10908327
- **Project number:** 5R01HL157741-04
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Long-Sheng Song
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $608,195
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10908327

## Citation

> US National Institutes of Health, RePORTER application 10908327, ERK1/2-Integrin Signaling in Desmosome-Dyad Crosstalk (5R01HL157741-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10908327. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*